JP2006514038A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514038A5
JP2006514038A5 JP2004562599A JP2004562599A JP2006514038A5 JP 2006514038 A5 JP2006514038 A5 JP 2006514038A5 JP 2004562599 A JP2004562599 A JP 2004562599A JP 2004562599 A JP2004562599 A JP 2004562599A JP 2006514038 A5 JP2006514038 A5 JP 2006514038A5
Authority
JP
Japan
Prior art keywords
reaction
free
protection
process according
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004562599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/041603 external-priority patent/WO2004058792A1/en
Publication of JP2006514038A publication Critical patent/JP2006514038A/ja
Publication of JP2006514038A5 publication Critical patent/JP2006514038A5/ja
Pending legal-status Critical Current

Links

JP2004562599A 2002-12-23 2003-12-23 ３’−ヌクレオシドプロドラッグの生産方法 Pending JP2006514038A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43615002P 2002-12-23 2002-12-23
PCT/US2003/041603 WO2004058792A1 (en) 2002-12-23 2003-12-23 Process for the production of 3'-nucleoside prodrugs

Publications (2)

Publication Number Publication Date
JP2006514038A JP2006514038A (ja) 2006-04-27
JP2006514038A5 true JP2006514038A5 (https=) 2007-01-18

Family

ID=32682350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004562599A Pending JP2006514038A (ja) 2002-12-23 2003-12-23 ３’−ヌクレオシドプロドラッグの生産方法

Country Status (16)

Country Link
US (1) US20040181051A1 (https=)
EP (1) EP1575971A4 (https=)
JP (1) JP2006514038A (https=)
KR (1) KR20050110611A (https=)
CN (1) CN100335492C (https=)
AU (1) AU2003300434A1 (https=)
BR (1) BR0316868A (https=)
CA (1) CA2511616A1 (https=)
IL (1) IL169314A0 (https=)
MX (1) MXPA05006865A (https=)
NO (1) NO20053557L (https=)
NZ (1) NZ540913A (https=)
PL (1) PL377608A1 (https=)
RU (1) RU2005123395A (https=)
WO (1) WO2004058792A1 (https=)
ZA (1) ZA200505040B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
US7595390B2 (en) * 2003-04-28 2009-09-29 Novartis Ag Industrially scalable nucleoside synthesis
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
JP5089395B2 (ja) * 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 治療用フロピリミジンおよびチエノピリミジン
AU2005322242B2 (en) * 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
EP1863500A2 (en) 2005-03-29 2007-12-12 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
WO2007039413A2 (en) * 2005-09-22 2007-04-12 F. Hoffmann-La Roche Ag Selective o-acylation of nucleosides
WO2007095269A2 (en) * 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
JP2009532411A (ja) 2006-04-04 2009-09-10 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖ治療のための３’，５’−ジ−ｏ−アシル化ヌクレオシド
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
SG172921A1 (en) 2009-01-09 2011-08-29 Univ Cardiff Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
KR20210096160A (ko) * 2018-11-25 2021-08-04 티엔티 메디칼 코포레이션 젬시타빈의 경구 활성 전구약물

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) * 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562543B1 (fr) * 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
CA2083961A1 (en) * 1990-05-29 1991-11-30 Henk Van Den Bosch Synthesis of glycerol di- and triphosphate derivatives
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5157027A (en) * 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5696277A (en) * 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
IL129126A0 (en) * 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
KR100719606B1 (ko) * 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CZ298681B6 (cs) * 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
WO2001018013A1 (en) * 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
US6566365B1 (en) * 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
CA2396713A1 (en) * 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
US6495677B1 (en) * 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
CN1427722A (zh) * 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
EP1964569A3 (en) * 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) * 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1326594A2 (en) * 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
NZ575481A (en) * 2000-10-18 2010-10-29 Pharmasset Inc Simultaneous quantification of nucleic acids in diseased cells
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2002057425A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
KR20040094692A (ko) * 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
RU2004128943A (ru) * 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
US7247621B2 (en) * 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
AU2003232071A1 (en) * 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
PL374781A1 (en) * 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MXPA04012779A (es) * 2002-06-28 2005-08-19 Idenix Cayman Ltd Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
AU2003279797B2 (en) * 2002-09-30 2009-10-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
HUE033832T2 (en) * 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
RU2005121904A (ru) * 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов

Similar Documents

Publication Publication Date Title
JP2006514038A5 (https=)
RU2005123395A (ru) Способ получения 3-нуклеозидных пролекарств
JP4768132B2 (ja) ［２．２．１］ビシクロヌクレオシドの改良された製法
JP2621123B2 (ja) ２’‐ジデオキシ‐イソグアノシン類，イソステリック類似体およびイソグアノシン誘導体並びにそれらの使用
US6686461B1 (en) Triphosphate oligonucleotide modification reagents and uses thereof
JP2002516256A (ja) 二環式糖成分を有する新規ヌクレオシド
JPH08225589A (ja) 修飾オリゴヌクレオチド、それらの製造、およびそれらの使用
WO2003062257A1 (en) Deazapurine nucleoside analogs and their use as therapeutic agents
JPH11501287A (ja) 光に不安定な保護基を有するヌクレオシド誘導体
CA2391279A1 (en) Synthesis of 2'-deoxy-l-nucleosides
CN100558739C (zh) 合成被保护的3’-氨基核苷单体
JP2022534561A (ja) アミノピリミジン化合物の調製方法
WO2003051898A1 (en) Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents
JP2003514766A (ja) 活性剤としてルイス酸を用いるオリゴヌクレオチド合成
Guo et al. Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents
JP4887500B2 (ja) ヌクレオシド類似体またはその塩
KR20200100033A (ko) 변형된 뉴클레오시드 포스포르아미다이트
Srivastava et al. Achiral, acyclic nucleic acids: synthesis and biophysical studies of a possible prebiotic polymer
JP2013531665A (ja) オリゴヌクレオチド合成のためにｎ−チオ化合物を用いる新規な方法
Komatsu et al. An efficient amination method for manufacturing cytidines
JP4885963B2 (ja) ヌクレオシドの選択的ｏ−アシル化
JP4174895B2 (ja) ヌクレオシド誘導体とその製法
JP2003513101A (ja) 感光性保護基を有するヌクレオシド誘導体
WO2020029647A1 (zh) 核苷化合物与其中间体的合成方法
JP2006131596A (ja) ヌクレオチド及びその誘導体の製造方法